Hyderabad emerges as top COVID-19 research destination

The DBT and BIRAC invited applications for the Covid-19 Research Consortium and in the first phase they received around 500 applications from academia and Industry.
For representational purposes (Photo | PTI)
For representational purposes (Photo | PTI)

HYDERABAD:  Hyderabad has emerged as a top destination for Covid-19 research, as four of the 16 life sciences companies from the country selected for funding as part of the Covid-19 Research Consortium by Biotechnology Industry Research Assistance Council (BIRAC) and Department of Biotechnology, are from the city.

The four companies are — vaccine manufacturer Bharat Biotech Ltd for utilising inactivated rabies vector platform, Virchow Biotech for the production of purified immunoglobulin G (IgG) at commercial scale from Covid-19 convalescent sera and production of high titres of equine hyper immune globulin for the treatment of Covid- 19 patients on a large scale, University of Hyderabad incubated start-up OncoSeek Bio for developing in-vitro Lung Organoid model, and Huwel Lifesciences for the development of rapid diagnostic testing kits.

The DBT and BIRAC invited applications for the Covid-19 Research Consortium and in the first phase they received around 500 applications from academia and Industry.

The multi-tiered review process is still ongoing and till date 16 proposals of devices, diagnostics, vaccine candidates, therapeutics and other interventions have been recommended for receiving funding support.

Related Stories

No stories found.

X
The New Indian Express
www.newindianexpress.com